- Pop Queen Whitney Houston Dies on Eve of Grammys
- Greek Debt Saga Back on Center Stage for Markets
- Greece Now Struggles to Overcome Mistrust
- Low-Interest Loans to European Banks Prompt Concern
- British Bankers Arrested in Tax Probe
- The Fight Begins: Obama's Budget Going to Congress
- Fuel Removal Under Way on Italy Cruise Ship
- Boeing Frustrated With Dreamliner Glitch
- Pentagon Budget: $178.8 Bln for Warships, Fighter Jets
- US Stocks Avoid Closing Down Over 1%, Again
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
MOST SHARED
- Low-Interest Loans to European Banks Prompt Concern
- Sun Arrests Pile Pressure on Murdoch Media Empire
- Clashes as Greek Parliament Debates Bailout Law
- Lodgenet Interactive Media in Hotel Rooms
- Pop Queen Whitney Houston Dies on Eve of Grammys
- Charting the Market: 50 Percent Correction Ahead?
- Barbie: Where Fashion Week and Toy Fair Collide
- Whitney Houston, Superstar of Records, Films, Dies
MOST POPULAR
HOT ON FACEBOOK
Dendreon Shares Continue Upswing Despite Analyst Warning
Text Size 
An analyst sounded a warning note on shares of biotechnology company Dendreon on Monday, which have more than tripled in value since March 30, but the stock continued to rise.
A Food and Drug Administration panel endorsed Provenge, a prostate cancer vaccine, on March 30, saying there was evidence the drug could be an effective cancer fighter. The agency usually follows panel recommendations in evaluating new drug applications.
Brean Murray Carret & Co. analyst Jonathan Aschoff said the FDA would set a "dangerous double standard" by approving Provenge, which did not meet its primary goal in two phase III trials. He said the FDA rejected Pharmacyclics' new drug application for Xcytrin for not reaching its goals, but agreed to review the Provenge application.
Aschoff has "Sell" rating and a price target of $1.50 for shares of Seattle-based Dendreon, implying the stock will lose 91.7 percent of its value in the next year.
Five of the nine analysts reporting to Thomson Financial rate Dendreon stock at "Buy" or the equivalent. Two analysts rate it at "Neutral"-equivalent and two at "Sell"-equivalent.
Dendreon were up [DNDN
Loading...
()
] on the Nasdaq Stock Market. The stock hit a new all-time high of $21 shortly after the open Monday.
- Marketing clichés aside, sometimes diamonds are for investing.
- The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear.
- This list of the 10 most active cities for speed traps was compiled by Trapster.com. See if your town is there.
- This Valentine’s Day should prove a love fest for restaurants, as many couples will be dining out.
- Here’s a look at Westminster Kennel Club’s most successful breeds—and how much they cost.
- What kind of homes do celebrity couples share? Here’s our updated list. Take a look.
Data is a real-time snapshot *Data is delayed at least 15 minutes
